Clinical Trials Directory

Trials / Completed

CompletedNCT00000178

Multicenter Trial of Prednisone in Alzheimer's Disease

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
Sponsor
National Institute on Aging (NIA) · NIH
Sex
All
Age
0 Years
Healthy volunteers
Not accepted

Summary

This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.

Conditions

Interventions

TypeNameDescription
DRUGPrednisone

Timeline

First posted
1999-11-01
Last updated
2005-06-24

Locations

19 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00000178. Inclusion in this directory is not an endorsement.